Gossamer Bio Inc (NASDAQ:GOSS) saw an uptick in trading volume on Friday . 2,403,564 shares traded hands during trading, an increase of 335% from the previous session’s volume of 552,849 shares.The stock last traded at $20.48 and had previously closed at $20.00.

A number of research firms have commented on GOSS. Bank of America began coverage on shares of Gossamer Bio in a research note on Tuesday, March 5th. They set a “buy” rating and a $30.00 price objective for the company. Svb Leerink began coverage on shares of Gossamer Bio in a research note on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price objective for the company. Barclays began coverage on shares of Gossamer Bio in a research note on Tuesday, March 5th. They set an “overweight” rating and a $27.00 price objective for the company. Evercore ISI began coverage on shares of Gossamer Bio in a research note on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price objective for the company. Finally, Leerink Swann began coverage on shares of Gossamer Bio in a research note on Tuesday, March 5th. They set an “outperform” rating for the company. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $29.25.

In related news, CFO Bryan Giraudo purchased 6,000 shares of Gossamer Bio stock in a transaction dated Tuesday, February 12th. The stock was acquired at an average cost of $16.00 per share, with a total value of $96,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Russell J. Cox purchased 7,200 shares of Gossamer Bio stock in a transaction dated Tuesday, February 12th. The stock was bought at an average cost of $16.00 per share, with a total value of $115,200.00. The disclosure for this purchase can be found here. Insiders bought 14,750 shares of company stock valued at $236,000 over the last three months.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/gossamer-bio-goss-sees-large-volume-increase/2897162.html.

Gossamer Bio Company Profile (NASDAQ:GOSS)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Further Reading: Capital Gains

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.